Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
The DOI matches its Crossref record; 15 of the 17 references it cites were found in a registry or an index.
Abstract
Anti–PD-1 inhibitors have significant activity in metastatic melanoma. Responses often occur early and may be sustained. The optimal duration of treatment with these agents is unknown. Here, we report the case of a 51-year-old woman treated with pembrolizumab, as part of the Keynote-001 trial, as first-line treatment for metastatic disease. She experienced a complete response after 13.8 months of treatment with no adverse events. One month after the last drug infusion and 18 months from starting treatment, the patient presented with eosinophilic fasciitis. She then developed acute confusion and weakness, thought to be due to intracranial vasculitis. High-dose steroids were initiated with resolution of the fasciitis. Aspirin was commenced for presumed vasculitis with resolution of the neurologic symptoms. To our knowledge, there are no previous reports of eosinophilic fasciitis or cerebral vasculitis due to anti–PD-1 agents. This case demonstrates that toxicity may occur in association with pembrolizumab treatment after a prolonged period of treatment without toxicity. Future trials should explore the optimal duration of treatment with pembrolizumab. Cancer Immunol Res; 4(3); 175–8. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“multiple recent reports of Eo-irAEs like eosinophilic fasciitis27-30 or eosinophilic granulomatosis with polyangiitis31 suggest that topical or low-dose oral corticosteroids, with or without CS-sparing treatments, can give excellent results.”
Citations
Cites
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 2×
“The incidence of grade 3–5 toxicity across different cohorts in Keynote-001 (2–4, 13) and Keynote006 (11) was 13%.”
BackgroundMethodSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392 · cited 2×
“Cancer Immunol Res; 4(3) March 2016 Cancer Immunology Research 176”
BackgroundSelf-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · cited 1×
“Emerging data from the Keynote-006 comparative study of ipilimumab (a CTLA-4 inhibitor) and pembrolizumab have shown superiority of first-line pembrolizumab in response rates and survival (5).”
MethodSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 1×
“Ipilimumab was FDA approved in 2010 and has shown durable responses beyond 3 years in a subset of patients (1).”
BackgroundRobert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Self-citationLäubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319 · cited 1×
“Rare toxicities in individual patients of type 1 diabetes (14) or myocarditis and cardiac failure (15) due to pembrolizumab have also been reported.”
BackgroundEosinophilic Skin Diseases: A Comprehensive Review
Long, H., Zhang, G., Wang, L., & Lu, Q. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8485-8 · Cited by 171 · cited 1×
“Eosinophilic fasciitis is a rare disorder of unknown etiology characterized by painful symmetrical swelling and thickening of the skin in the distal extremities and rarely the trunk and neck (7).”
BackgroundRibas, A., Hodi, F. S., Kefford, R., Hamid, O., Daud, A., Wolchok, J. D., Hwu, W.-J., Gangadhar, T. C., Patnaik, A., Joshua, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba9000 · Cited by 147
Self-citationAnti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Martín-Liberal, J., Furness, A. J. S., Joshi, K., Peggs, K. S., Quezada, S. A., & Larkin, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1689-1 · Cited by 137 · cited 1×
“Rare toxicities in individual patients of type 1 diabetes (14) or myocarditis and cardiac failure (15) due to pembrolizumab have also been reported.”
BackgroundWeber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J. M. G., Sznol, M., Liu, H. Y., Waxman, I., & Robert, C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9018 · Cited by 103 · cited 1×
“The majority of toxicities, particularly immune-related adverse events (IrAE), appear to occur in the first 6 months of treatment, but toxicity may occur later with ongoing therapy (6).”
Background
Cited by
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
“exacerbation of multiple sclerosis [26], brain vasculitis [27], and PRES-like syndromes [28].”
BackgroundCappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2017) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 403
“Another patient who presented with myalgias was ultimately found to have eosinophilic fasciitis (26).”
BackgroundHassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T. K., Grimm, M.-O., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 331
Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review
Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011795 · Cited by 273
Metadata
- Authors
- Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., & Hogg, D.
- Affiliations
- Princess Margaret Cancer Centre (CA)
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2016-02-29
- Volume
- 4
- Issue
- 3
- Pages
- 175-178
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2270309512
- Semantic Scholar
- 1fde54dae8de2941ed772180770aa04df7fc2cab
- Cited by
- 109
- References
- 17
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 12 · 2020: 15 · 2019: 15 · 2018: 16 · 2017: 14 · 2016: 8
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Keywords
- eosinophilic fasciitis, pembrolizumab, PD-1 inhibitors, metastatic melanoma, acute encephalopathy, cerebral vasculitis, immune checkpoint inhibitor toxicity, treatment duration, corticosteroid therapy, aspirin, KEYNOTE-001
- MeSH terms
- Antineoplastic Agents, Brain Diseases, Eosinophilia, Fasciitis, Female, Humans, Melanoma, Middle Aged, Skin Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0186
- The paper
- Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A. S., Al-Faraidy, N., Butler, M. O., Rogalla, P., Mason, W., Joshua, A. M., & Hogg, D. (2016). Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.